» Articles » PMID: 29523809

Factors Associated with Prostate Specific Antigen Testing in Australians: Analysis of the New South Wales 45 and Up Study

Overview
Journal Sci Rep
Specialty Science
Date 2018 Mar 11
PMID 29523809
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Australia has one of the highest incidence rates of prostate cancer (PC) worldwide, due in part to widespread prostate specific antigen (PSA) testing. We aimed to identify factors associated with PSA testing in Australian men without a diagnosis of prostate cancer or prior prostate disease. Participants were men joining the 45 and Up Study in 2006-2009, aged ≥45 years at recruitment. Self-completed questionnaires were linked to cancer registrations, hospitalisations, health services data and deaths. Men with a history of PC, radical prostatectomy or a "monitoring" PSA test for prostate disease were excluded. We identified Medicare reimbursed PSA tests during 2012-2014. Multivariable logistic regression was used to estimate adjusted odds ratios (OR) for the association between having PSA tests and factors of interest. Of the 62,765 eligible men, 51.8% had at least one screening PSA test during 2012-2014. Factors strongly associated with having a PSA test included having 27+ general practitioner consultations (versus 3-9 consultations; OR = 2.00; 95%CI = 1.90-2.11), benign prostatic hyperplasia treatment (versus none; OR = 1.59(95%CI = 1.49-1.70), aged 60-69 years (versus 50-59 years; OR = 1.54; 95%CI = 1.48-1.60). These results emphasise the important role of primary care in decision making about PSA testing.

Citing Articles

Knowledge and practices regarding prostate cancer screening in Spanish men: The importance of personal and clinical characteristics (PROSHADE study).

Parker L, Caballero-Romeu J, Chilet-Rosell E, Hernandez-Aguado I, Gomez-Perez L, Alonso-Coello P PLoS One. 2024; 19(5):e0303203.

PMID: 38814917 PMC: 11139292. DOI: 10.1371/journal.pone.0303203.


Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study.

Nair-Shalliker V, Bang A, Egger S, Yu X, Chiam K, Steinberg J Br J Cancer. 2022; 127(4):735-746.

PMID: 35610365 PMC: 9381576. DOI: 10.1038/s41416-022-01827-1.


Effect of Perceived Self-Vulnerability on Prostate Cancer Screening Uptake and Associated Factors: A Cross-Sectional Study of Public Health Facilities in Western Kenya.

Opondo C, Onyango P, Asweto C Ann Glob Health. 2022; 88(1):12.

PMID: 35281883 PMC: 8855733. DOI: 10.5334/aogh.3064.


Preferences for More or Less Health Care and Association With Health Literacy of Men Eligible for Prostate-Specific Antigen Screening in Australia.

Pickles K, Scherer L, Cvejic E, Hersch J, Barratt A, McCaffery K JAMA Netw Open. 2021; 4(10):e2128380.

PMID: 34636915 PMC: 8511975. DOI: 10.1001/jamanetworkopen.2021.28380.


Prostate-specific antigen (PSA) screening rates and factors associated with screening in Eastern Canadian men: Findings from cross-sectional survey data.

Tchir D, Farag M, Szafron M Can Urol Assoc J. 2020; 14(7):E319-E327.

PMID: 32017690 PMC: 7337718. DOI: 10.5489/cuaj.6072.


References
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

2.
Holden C, McLachlan R, Pitts M, Cumming R, Wittert G, Agius P . Men in Australia Telephone Survey (MATeS): a national survey of the reproductive health and concerns of middle-aged and older Australian men. Lancet. 2005; 366(9481):218-24. DOI: 10.1016/S0140-6736(05)66911-5. View

3.
Banks E, Jorm L, Rogers K, Clements M, Bauman A . Screen-time, obesity, ageing and disability: findings from 91 266 participants in the 45 and Up Study. Public Health Nutr. 2010; 14(1):34-43. DOI: 10.1017/S1368980010000674. View

4.
McDowell M, Occhipinti S, Gardiner R, Chambers S . Patterns of prostate-specific antigen (PSA) testing in Australian men: the influence of family history. BJU Int. 2012; 109 Suppl 3:64-70. DOI: 10.1111/j.1464-410X.2012.11050.x. View

5.
Trevena J, Rogers K, Jorm L, Churches T, Armstrong B . Quantifying under-reporting of pathology tests in Medical Benefits Schedule claims data. Aust Health Rev. 2013; 37(5):649-53. DOI: 10.1071/AH13092. View